



NEWS RELEASE

Teijin Regenet and iPS Portal Finalize Consignment Agreement for Contract Manufacturing of Autologous iPS Cells

iPS Portal to Launch Bio-Resource Reserve, a New Service Encompassing Production and Long-term Storage of Autologous iPS Cells

Tokyo, March 16 2026 –[iPS Portal, Inc](#), a life sciences company, and [Teijin Regenet Co., Ltd.](#), a contract development and manufacturing organization (CDMO), today announced they have finalized a consignment agreement for manufacturing autologous induced pluripotent stem (iPS) cells. These cells, created by introducing several genes into human somatic cells (e.g., skin or blood cells), can proliferate almost infinitely and are capable of differentiating into cells of various tissues and organs. Contract manufacturing provided by Teijin Regenet will help iPS Portal establish a system for future mass production of high-quality iPS cells.

In conjunction with this agreement, iPS Portal will launch in April 2026 a new service called Bio-Resource Reserve (BRR) for manufacturing and banking iPS cells on behalf of individuals. Because the iPS cells manufactured through BRR will serve as raw materials for therapeutic products, the new service will provide infrastructure and support for companies developing autologous iPS cell-based therapies.


Since iPS cells were first reported in 2006 by Professor Shinya Yamanaka of Kyoto University, intensive research has been conducted. Based on conditional and time-limited approval of two products by Japan's Ministry of Health, Labour and Welfare this year, commercialization of iPS cell-based products for various disease areas is expected in the future. Because the quality of iPS cells depends on the individual's age and health status, generating and storing iPS cells while the individual is still young and healthy may increase their likelihood of enabling safer and more-effective therapies.

By consulting with pharmaceutical affairs experts regarding quality standards and controls in the manufacturing process, and by manufacturing and storing iPS cells according to a quality control and management system envisioned for clinical use, iPS Portal will ensure the cells produced by Teijin Regenet are optimal for use as raw materials in therapeutics.

Further, in preparation for manufacturing iPS cells at its Iwakuni Factory, Teijin Regenet is receiving a technology transfer from iPS Portal regarding iPS cell production and quality testing. Working together, the companies will establish a manufacturing framework by autumn 2026.

In April 2026, iPS Portal will begin accepting applications from interested individuals for the BRR service via its website. After the contract is concluded, a medical institution will

collect blood, and Teijin Regenet will manufacture autologous iPS cells from the somatic cells in the blood. The iPS cells produced will be stored by the iPS Portal. iPS Portal and Teijin Regenet aim to secure orders and manufacture iPS cells for 20 individuals in 2026, and expand the service to 1,000 by fiscal 2030.



Process flow of the iPS cell storage service provided by iPS Portal



iPS Portal Head Office (company name plate)



Teijin Regenet "Iwakuni Factory"

About the iPS Portal

iPS Portal, headquartered in Kyoto, Japan, is engaged in businesses related to the field of regenerative medicine, funded by local governments (Kyoto Prefecture and Kyoto City) and major companies from various industries. Building on cutting-edge biotechnologies such as iPS cells, the company provides support services related to research, development and commercialization, while building relationships with many companies and universities both within and outside the regenerative medicine industry.

About the Teijin Regenet

Teijin Regenet is a Teijin Group company, established in 2023 and dedicated exclusively to providing contract development and manufacturing services for Cell & Gene Therapy and Regenerative Medicines (CGT & RM). By leveraging the industrialization platform for CGT & RM products the company is building together with academia and companies in Japan and overseas, as well as both "Kashiwa-no-ha Facility" (Kashiwa City, Chiba Prefecture) and "Iwakuni Factory" (Iwakuni City, Yamaguchi Prefecture), the company

provides CDMO services that offer one-stop support from manufacturing process development to product manufacturing for startup companies and pharmaceutical companies.

About the Teijin Group

Teijin (TSE: 3401) is a technology-driven global group with two core businesses: high-performance materials and healthcare solutions. Established in 1918 as Japan's first rayon manufacturer, Teijin today comprises some 150 companies employing 20,000 people. Teijin is committed to its Purpose, "Pioneering solutions together for a healthy planet." Teijin works together with employees and external partners to achieve its Long-Term Vision, "To be a company that supports the society of the future." Teijin posted consolidated revenue of JPY 1,005.5 billion and total assets of JPY 1,061.3 billion in the fiscal year ending March 31, 2025.

Press Contact

Corporate Communication Department
Teijin Limited
pr@teijin.co.jp